Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and immunosuppressive mechanisms may limit the therapeutic efficacy of sorafenib in HCC. We used a syngeneic mouse liver cancer cell line to establish orthotopic liver or subcutaneous tumors to study how proinflammatory and immunosuppressive mechanisms impact on the efficacy of sorafenib. We found sorafenib exhibited a potent therapeutic effect in subcutaneous tumors, but a less potent effect in orthotopic liver tumors. The protein levels of interleukin-6 (IL-6) and vascular endothelial growth factor A (VEGF-A) were persistently elevated in orthotopic liver tumors, but not in subcutaneous tumors, treated with sorafenib. Likewise, the tumor-infiltrating Ly6G 1 myeloid-derived suppressor cells (MDSCs) and immune suppressors were increased in orthotopic liver tumors, not in subcutaneous tumors, treated with sorafenib. The tumor-infiltrating Ly6G
Hepatocellular carcinoma (HCC) is an important malignant disease worldwide, especially in East Asian and African countries. 1 Sorafenib, a multikinase inhibitor with antiangiogenic activity by targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor, and Raf kinase, 2 is currently the most widely used systemic therapy for advanced HCC. 3, 4 However, the clinical efficacy of sorafenib against HCC is modest. Many HCC patients either do not respond to sorafenib treatment or have a short-lived disease stabilization. Previous studies have focused on the activation of alternative or parallel proangiogenic pathways to VEGF/ VEGFR signaling such as the fibroblastic growth factor receptor (FGFR) signaling in mediating resistance to sorafenib. [5] [6] [7] [8] Other mechanisms contributing to sorafenib resistance have been under active investigation. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are defined by their myeloid lineage, immature status and immunosuppressive ability; they have been demonstrated to play significant roles in immunosuppression, proangiogenesis and tumor progression. [9] [10] [11] [12] [13] [14] MDSCs have also been shown to mediate resistance to antiangiogenic therapies in preclinical studies of various cancer types. 15, 16 Several studies have reported that sorafenib could enhance the antitumor immunity by modulating MDSCs in preclinical models of HCC. 17, 18 However, Chen et al. 19 demonstrated that sorafenib increased the infiltration of Gr1 1 MDSCs through the interaction of stromal-derived factor-1 (SDF-1) and CXC receptor type 4 in an orthotopic mouse liver cancer model. They also showed that myeloid differentiation antigen (Gr-1) 1 MDSCs promoted tumor fibrosis and contributed to a decreased efficacy of sorafenib. 19 In the current study, we used a syngeneic mouse liver cancer model to study the significance of tumor-infiltrating MDSCs in affecting the therapeutic effect of sorafenib. We found that the tumor-infiltrating MDSCs were increased in orthotopic liver tumors treated with sorafenib, and the immunosuppressive property of the tumor-infiltrating Ly6G 1 MDSCs could attenuate the therapeutic effect of sorafenib. We also demonstrated that antibody-mediated therapy targeting Ly6G
1 MDSCs or interleukin (IL)-6 improved the efficacy of sorafenib against liver cancer.
Material and Methods
Cell lines, animals and tumor model BNL, a mouse liver cancer cell line (ATCC TIB-75) kindly provided by Professor Lih-Hwa Hwang (National Yang-Ming University, Taipei, Taiwan) 20 was used to generate syngeneic mouse liver cancers in immunocompetent mice. Six-week-old male BALB/cByJNarl mice, purchased from the National Laboratory Animal Center (Taipei, Taiwan), were used in these experiments. T-cell receptor (TCR) transgenic mice DO11.10 (H-2d) bearing the TCR-recognized ovalbumin (OVA) 323-339 peptide were kindly provided by Professor Bor-Luen Chiang (National Taiwan University Hospital, Taipei, Taiwan). To generate orthotopic liver cancers, we directly inoculated BNL cells into the livers of BALB/cByJNarl mice as previously described. 20 All animal experiments were performed according to the guidelines of the Animal Care and Use Committee of the National Taiwan University College of Medicine.
Sorafenib treatment in vivo
Seven days or 14 days after the tumor cells were implanted in the liver or subcutaneous tissue, respectively, mice were orally fed with sorafenib (LC Laboratories, Woburn, MA) at the doses of 5 mg/kg/day or its solvent vehicle (Cremophor EL/95% ethanol in 50:50; Sigma-Aldrich, St. Louis, MO) daily for 1 or 3 weeks. Combination therapies were performed by administering sorafenib or vehicle control combined with neutralizing antibodies targeting Ly6G or IL-6 (i.e., anti-mouse Ly6G Ab or anti-mouse IL-6 Ab, respectively) or their corresponding isotype control antibodies (Bio X Cell, West Lebanon, NH). Antibody-based therapeutics were commenced from the fourth day after tumor cell implantation, with a loading dose of 25 mg/kg administered intraperitoneally (ip) followed by 4 mg/ kg ip every 3 days for a total of seven doses. At the end of the experiments, the mice were sacrificed. Tumors were excised from the liver and weighed to obtain their mass (g).
Cell isolation
The mice were sacrificed to collect tumors, livers, spleens, femurs and tibias (for bone marrow [BM] ) to enrich leukocytes by employing methods described previously. 20, 21 Whole blood (WB), collected through cardiac puncture, was suspended with an ammonium-chloride-potassium buffer to lyse red blood cells.
Flow cytometry
Leukocytes isolated from different tissues or T cells activated through in vitro stimulation were analyzed using surface marker staining alone or combined with intracellular cytokine staining by adopting methods described previously 20 to identify different cell subsets and their cytokine presentation. The antibodies used in our study are described in the Supporting Information Material section.
Cytospin and morphology analysis
Tumor-infiltrating leukocytes (TILs) were isolated as previously described and were then processed using the mouse MDSC isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) to separate the Gr-1 high Ly6G 1 myeloid cells
What's new?
The multi-kinase inhibitor sorafenib is an approved agent for the treatment of liver cancer. Using a syngeneic mouse liver cancer model, the authors found less therapeutic efficacy of sorafenib in orthotopic liver tumors as compared to subcutaneous tumors. They attributed this to increased levels of proinflammatory cytokines and immunosuppressive myeloid-derived suppressor cells found in orthotopic tumors, conditions that when suppressed increased sorafenib's therapeutic efficiency. The authors propose targeting the immunosuppressive tumor microenvironment as a novel therapeutic approach for liver cancers.
from the Gr-1 dim Ly6G -myeloid cells for the subsequent experiments. The TILs were analyzed using cytospin by employing a Shandon Cytospin III centrifuge (Thermo Fisher Scientific, Inc., Rockford, IL). Cells were immediately stained with Liu's staining, 22 and cell morphology was examined using a Zeiss Axio Observer D1 microscope and analyzed using AxioVision software (Carl Zeiss, Chester, VA).
Cytokine detection
Cytokines were isolated from tumor tissues according to a previously described method. 23 A cytokine bead array (BD Biosciences Pharmingen, San Jose, CA) was applied to analyze levels of IL-1b, IL-3, IL-4, IL-5, IL-6, IL-12, IL-13 and TNFa. The amount of VEGF, SCF, G-CSF or TGF-b was determined using ELISA kits (Peprotech, Rocky Hill, NJ) according to the manufacturer's instructions. The concentration of each protein was normalized with the total protein determined using a bicinchoninic acid (BCA) protein analysis kit (Thermo Fisher Scientific).
Immunosuppression analysis of Ly6G
1 MDSCs
The immunosuppression of Ly6G 1 MDSCs was analyzed using T-cell proliferation, immunosuppressive CD4
1 T-cell induction and cytotoxic CD8
1 T-cell suppression. Employing methods, described previously, 20 were detailed in the Supporting Information Material section.
Quantitative real-time reverse-transcriptase polymerase chain reaction
Purified Ly6G
1 MDSCs were homogenized in TRIzol reagent (Invitrogen), and total RNA was extracted and treated using a TURBO DNA-free kit to remove contaminated genomic DNA according to the manufacturer's instructions. Subsequently, reverse transcription was performed using PrimeScript RT master mix (Takara Bio, Kyoto, Japan) to determine relative quantities of mRNA. TaqMan Master Mix Premix Ex Taq (Takara Bio) and predesigned primers and fluorescein-labeled probe sets were used in our study and are described in the Supporting Information Material section.
In vitro culture of Ly6G
1 MDSCs from mouse BM Ly6G 1 cells were isolated from BM of liver tumors-bearing mice treated with vehicle, followed by purification of Ly6 
Statistical analysis
Data are obtained from 3 independent experiments unless otherwise specified and are expressed as mean 6 standard deviations. The statistical testing was examined by two-tailed unpaired t-test or one-sample t-test using the Statistical Package of GraphPad Prism PRISM 5.0 (GraphPad Software, Inc, San Diego, CA). Statistical significance was marked as * when p < 0.05, ** when p < 0.01 and *** when p < 0.001.
Results

Therapeutic effect of sorafenib was less potent in orthotopic mouse liver tumors than in subcutaneous tumors
To monitor the effect of sorafenib in suppressing liver cancer growth, we treated the BNL mouse orthotopic liver tumors or subcutaneous tumors from the 8th day or 14th day after implanting tumor cells for 1-3 weeks (Fig. 1a) . We found that sorafenib exhibited antitumor effects in both models. However, the therapeutic effects of sorafenib were more potent in subcutaneous BNL tumors than in orthotopic liver tumors. As shown in Figure 1b , subcutaneous tumors treated with sorafenib at the dose of 5 mg/kg/day were effectively suppressed through the treatment course, with the tumor burden ratios (the tumor weight of mice treated with sorafenib divided by that of mice treated with the vehicle) of 0.26 6 0.02 at 1 week of sorafenib treatment and 0.19 6 0.02 at the 3 week of sorafenib treatment, respectively. On the other hand, the tumor burden ratios of orthotopic liver tumors treated with sorafenib were 0.39 6 0.12 at 1 week of sorafenib treatment and 0.70 6 0.15 at 3 week of sorafenib treatment, respectively. These data suggested that the therapeutic effect of sorafenib was partially attenuated in orthotopic liver tumors compared to tumors established subcutaneously.
The orthotopic mouse liver tumors treated with sorafenib expressed increased levels of proinflammatory and immunosuppresive cytokines
To study whether inflammation and immunosuppression might have occurred and contributed to the less effectiveness of sorafenib in mouse orthotopic liver tumors, we analyzed the expression levels of a panel of inflammatory cytokines and soluble factors in liver tumor tissues treated with sorafenib or the vehicle (Fig. 1c, Supporting Information Fig. 1 ). We found that IL-6 and VEGF-A were persistently elevated in liver tumors treated with sorafenib from 1 week of treatment to the end of 3 week treatment (Fig. 1c) . In addition, TGF-b, a well-known growth factor involving in tumor progression and immunosuppression, was significantly increased at 1 week of treatment, and trended to increase at 3 week of treatment (Fig. 1c) . On the contrary, the levels of IL-6, VEGF-A and TGF-b did not increase in subcutaneous tumors treated with sorafenib (Fig. 1c) .
The microenvironment of the orthotopic mouse liver tumors treated with sorafenib became toward immunosuppressive
We continued investigating whether the immunosuppressive microenvironment might underlie the differential efficacies of sorafenib in orthotopic and subcutaneous tumor models by characterizing their TILs. At 1 week after treated with sorafenib or vehicle in orthotopic tumor models, we observed both immune effector cells (including the CD4 1 or CD8 1 IFN-g-expressing T cell) and immunosuppressors (including the IL-10 or TGF-b-expressing CD4 1 T cell and forkhead box P3
[FOXP3]-expressing CD4 1 T cell) significantly increased in sorafenib-treated liver tumors (Fig. 2a) . On the other hand, in subcutaneous liver tumor models, we found that most subsets of TILs were not significantly different between sorafenib-treated and vehicle-treated subcutaneous liver tumors except the TGF-b-expressing CD4 1 T cells (Supporting Information Fig. 2A) . We calculated the ratio of total immune effectors versus total immunosuppressors and found that this total effector-to-suppressor ratio was significantly lower in the orthotopic liver tumors treated with sorafenib than those treated with the vehicle (Fig. 2b) . The total effector-to-suppressor ratio was not decreased in subcutaneous tumors treated by sorafenib (Supporting Information Fig. 2B ). To further confirm that this decreased effector-to-suppressor ratio in orthotopic liver tumors treated with sorafenib conferred an immunosuppressive status, we studied T-cell proliferation ability of TILs. As shown in Figure 2c significantly decreased T-cell proliferation stimulated by anti-CD3 and anti-CD28 antibodies was observed in the TILs isolated from sorafenib-treated liver tumors than those from vehicle-treated liver tumors. By contrast, the T-cell proliferation was significantly higher in the TILs isolated from sorafenib-treated subcutaneous tumors than those from vehicle-treated subcutaneous tumors (Supporting Information  Fig. 2C ). These data indicated that the microenvironment in orthotopic liver tumors, but not in subcutaneous tumors, tilted toward immunosuppression following treatment with sorafenib.
Ly6G
1 MDSCs increased significantly in the orthotopic liver tumors treated with sorafenib for 1 week
In studying the possible cellular mechanisms contributing to the immunosuppressive microenvironment of orthotopic liver tumors treated with sorafenib, we found that the proportion of CD11b 1 Gr-1 1 MDSCs increased significantly in orthotopic liver tumors of sorafenib-treated mice compared to the vehicle-treated group (Fig. 3a) . By cytospin and morphology analysis, we characterized that the majority of these MDSCs were Ly6G 1 and Ly6C low , the so-called PMN type of MDSCs (Fig. 3b) (Fig. 3c) . We also found that the expression levels of multiple genes involved in immunosuppression, including Arg I, NOS2, S100a8 and S100a9 (S100 calcium-binding protein A8/9), were increased in the Ly6G 1 MDSCs isolated from the liver tumors treated with sorafenib compared to those treated with the vehicle. In addition, the transcript of signal transducer and activator of transcription (Stat)3 was consistently increased in the Ly6G
1
MDSCs from sorafenib-treated tumors (Fig. 3d) . These results indicated that the Ly6G 1 MDSCs, expressing immunosuppressive characteristics, were the major subset of MDSCs accumulating in the orthotopic liver tumors treated with sorafenib. IL-6 signaling provided a key survival signal to sorafenibtriggered cell death and promoted immunosuppressive function in Ly6G 1 MDSCs IL-6 and VEGF-A have been shown to promote expansion and proliferation of MDSCs in tumors. 24 In our mouse liver cancer model, we found that the expression levels of IL-6 receptors (CD126, CD130 and the soluble forms of IL-6Ra) and VEGFR2 were significantly increased on the Ly6G Fig. 3A) . To delineate the mechanisms underlying the protective effect of IL-6 and VEGF on Ly6G 1 MDSCs, we studied the viability and cell signaling of the in vitro cultured BM-derived Ly6G 1 MDSCs treated with sorafenib ( Fig. 5a ). We found that IL-6 at the doses of 5 or 10 ng/mL effectively protected Ly6G 1 MDSCs from cell death induced by sorafenib, quantitated by 7AAD and Annexin V staining (Fig. 5b) . By contrast, VEGF up to 10 ng/mL did not abrogate the cell death induced by sorafenib in the Ly6G 1 MDSCs (Fig. 5b) . In cultured Ly6G 1 MDSCs treated with sorafenib, the presence of IL-6 abolished the sorafenib-mediated downregulation of p-Stat3, whereas the MDSCs by an anti-mouse Ly6G Ab in orthotopic mouse liver cancer model treated with sorafenib. The combination of antimouse Ly6G Ab plus sorafenib, compared to isotype Ab plus sorafenib or anti-mouse Ly6G plus vehicle, resulted in a significantly lower tumor burden (Fig. 6a) . The combination of antiLy6G Ab plus sorafenib yielded the lowest frequency of Ly6G
MDSCs in TILs from the liver tumors and in splenocytes (Figs. 6b and 6h), improved the immunosuppressive status indicated by the highest T-cell proliferation activity using TILs (Fig. 6c) and significantly decreased the protein levels of IL-6 and TGF-b, but not VEGF-A, in liver tumors (Fig. 6g) . We subsequently tested the efficacy of targeting IL-6 combined with sorafenib in the orthotopic liver tumor models. The combination of anti-IL-6 Ab plus sorafenib was significantly more potent in suppressing the liver tumor growth than other treatment groups (Fig. 6d) . The combination of anti-IL-6 Ab plus sorafenib yielded the lowest frequency of Ly6G 1 MDSCs in TILs from the liver tumors and in splenocytes (Figs. 6e and 6h) , improved the immunosuppressive status with the highest T-cell proliferation activity using TILs (Fig. 6f) and significantly decreased the protein levels of IL-6, VEGF-A and TGF-b in liver tumors (Fig. 6g) . On detailed evaluation of the characteristics of T cells in mouse liver tumors, we also found that the combination of anti-IL-6 Ab plus sorafenib yielded higher proportion of Ki-67-expressing CD8 1 T cells than other treatment groups, higher proportion of Tbet 
Discussion
In the current study, using syngeneic BNL mouse liver cancer model, we demonstrated the Ly6G 1 MDSC was the major subtype of tumor-infiltrating MDSCs and contributed to a less effectiveness of sorafenib in orthotopic liver tumors than in subcutaneous tumors through promoting an immunosuppressive tumor microenvironment. In addition, we showed that Ly6G
1 MDSCs depletion by anti-Ly6G Ab or anti-IL-6
Ab improved the therapeutic efficacy of sorafenib in orthotopic mouse liver tumors.
In the current study, we found that the persistent increase of IL-6, VEGF-A and TGF-b occurred in orthotopic BNL mouse liver tumors treated with sorafenib, but not in subcutaneous tumors treated with sorafenib. Our observation may suggest that the induction of proinflammatory, proangiogenic or immunosuppressive cytokines in response to sorafenib treatment could be tumor microenvironment specific. In a preliminary data using another mouse liver tumor model ML-1 4a , 25 we also found that the protein levels of IL-6 and VEGF-A were increased in orthotopic liver tumors treated with sorafenib but not in subcutaneous tumors (Supporting Information Fig. 6 ). However, many cell lineages in liver and HCC microenvironment have been reported to be able to produce inflammatory cytokines and proangiogenic factors to promote tumor progression, such as Kupffer cells, myeloid cells, tumor-associated macrophages and others. 14, 26, 27 Further studies are warranted to identify the cell types responsible for IL-6 and VEGF production in HCC microenvironment after sorafenib treatment so that the potential cellular targets can be further explored to improve the therapeutic efficacy of sorafenib.
Previous studies have revealed that sorafenib may augment antitumor immunity by reducing regulatory T cells or CD11b 
Gr-1
1 MDSCs in tumor-bearing mice. 17, 28 However, in our study, while we also found the number of Ly6G MDSCs was decreased in subcutaneous tumors treated with sorafenib ( Fig. 3c) 
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demonstrated that PMN-type cells involved in the resistance to sorafenib using preclinical liver cancer models and human HCC samples.
The well-known immunosuppressive mechanisms of Ly6C high Ly6G -/dim M-MDSC and Ly6C -/dim Ly6G high GMDSCs include the production of NO (nitric oxide), ROS (reactive oxygen species), Arg I or NADPH oxidase 2 (NOX2) to suppress T-cell function. 12, 29 Other immunosuppressive actions of MDSCs involve IL-10 or TGF-bexpressing CD4
1 T cells conversion, FOXP3-expressing regulatory T cell differentiation and expansion, and induction of CD8 1 T-cell tolerance. [30] [31] [32] [33] [34] [35] [36] In our study, we found that the sorafenib-treated liver tumor-derived Ly6G 1 MDSCs were capable of inducing IL-10-expressing and TGF-b-expressing CD4 1 T cells in specific Ag-induced T-cell activation ex vivo (Fig. 4) .
Expression of G-CSF, Bv8, IL-8, hypoxia-inducing factor 1a and SDF-1 has been demonstrated to mobilize CD11b 
Gr-1
1 MDSCs into tumor microenvironment to promote tumor progression. 9, 11 Previous studies have also revealed that IL-6 participates in MDSCs expansion 24 and MDSCs transmigration in hypoxic tumor microenvironment. 37 IL-6 is a pleiotropic inflammatory cytokine that participates in multiple normal physiological functions 38 and Figure 6 . Continued.
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plays an important role in promoting tumor progression 39, 40 through Stat3-dependent signaling pathway. 41 In our study, we demonstrated that IL-6 (Fig. 1c) was elevated in orthotopic liver tumors treated with sorafenib, the expression levels of IL-6 receptors and the downstream p-Stat 3 were significantly increased in Ly6G 1 MDSCs isolated from orthotopic liver tumors treated with sorafenib (Supporting Information Fig. 3 ) and IL-6 provided survival signals to sorafenibinduced apoptosis in cultured Ly6G
1 MDSCs (Fig. 5) . Our data support the critical role of IL-6 signaling in the expansion, survival, and functioning of the tumor-infiltrating Ly6G
1 MDSCs in attenuating the therapeutic efficacy of sorafenib in orthotopic mouse liver tumors.
Recently, immunotherapy especially immune checkpoint blockade has emerged as a new paradigm of cancer therapy. 42 In September 2017, the Food and Drug Administration of the United States granted an accelerated approval of nivolumab for HCC patients previously treated with sorafenib. Nivolumab, an antibody targeting programmed cell death protein 1 (PD-1) has been shown to exhibit an objective tumor response of 20% in advanced HCC patients. 43 The anti-IL-6 antibody-mediated sorafenib-sensitizing effect is worthy of further clinical validation because several antibodies targeting IL-6/IL-6 receptor have been commercialized for treating human diseases. 44, 45 Furthermore, given the facts that both MDSCs and IL-6 play significant roles in promoting tumor growth through immunosuppression and angiogenesis, their roles in affecting the efficacy of immune checkpoint blockade as cancer therapy may warrant further investigations.
In conclusion, we demonstrated that sorafenib treatment was associated with an increase of proinflammatory cytokine IL-6 and immune suppressive Ly6G 
